<DOC>
	<DOCNO>NCT00288990</DOCNO>
	<brief_summary>Study Title : A Serologic Study Correlate b-IFN NAb titer b-IFN Induced Biomarker Response Patients Multiple Sclerosis Objectives : Subjects currently three b-IFN preparation ( Avonex ( Interferon b-1a 30 mcg IM Q 7 day ) , Rebif ( Interferon b-1a 22 44mcg SC TIW ) , Betaseron ( Interferon b-1b 250mcg SC QOD ) ) enrol one 3 group : Group 1 : Approximately 200 subject enrol NAb+ ( titer ³ 20NU/ml ) Group 2 : Approximately 50 subject enrol BAb- ( titer &lt; 8U ) NAb- ( titer &lt; 20 NU/ml ) Group 3 : Approximately 50 subject enrol BAb+ ( titer ³8U ) NAb- ( titer &lt; 20 NU/ml ) The primary objective study compare baseline b-IFN induce MxA mRNA response neutralize antibody positive ( NAb+ , titers ³ 20NU/ml , Group 1 ) vs. antibody negative ( NAb- , titer &lt; 20NU/ml , BAb- , titer &lt; 8U , Group 2 ) patient . Secondary objective : 1 . To compare b-IFN induced MxA mRNA response neutralize antibody positive ( NAb+ , titers ³ 20NU/ml , Group 1 ) vs. antibody negative ( NAb- , titer &lt; 20NU/ml , BAb- , titer &lt; 8U , Group 2 ) patient month 6 visit . 2 . To compare b-IFN induced biomarker response ( viperin , IFIT1 ) neutralize antibody positive ( NAb+ , titers ³ 20NU/ml , Group 1 ) vs. antibody negative ( NAb- , titer &lt; 20NU/ml , BAb- , titer &lt; 8U , Group 2 ) patient ( data compare baseline month 6 visit ) 3 . To compare b-IFN induced biomarker response ( MxA , viperin , IFIT1 ) neutralize antibody positive ( NAb+ , titers ³ 20NU/ml , Group 1 ) vs. BAb+ ( titer ³8U ) /NAb- ( titer &lt; 20 NU/ml , Group 3 ) patient baseline month 6 visit . 4 . To correlate NAb titer level b-IFN induce biomarker response ( data take baseline month 6 visit Group 1 ) . 5 . To compare b-IFN induced biomarker response ( MxA , viperin , IFIT1 ) BAb-/NAb- patient ( Group 2 ) vs. BAb +/NAb- patient ( Group 3 ) order determine BAbs affect b-IFN induced biomarker response ( data compare baseline month 6 visit ) . Tertiary objective : 1 . To explore patient characteristic may predict NAb positivity . Design : This multi-center , open-label study approximately 300 ( 200 NAb+ 100 NAb- ( 50 BAb+ 50 BAb- ) ) MS patient compare b-IFN induced biomarker response follow b-IFN injection neutralize antibody positive vs. antibody negative patient . Study Population : Approximately 300 subject ( 200 Group 1 , 50 Group 2 , 50 Group 3 ) recruit study . Inclusion Criteria : To eligible entry study , candidate must meet following eligibility criterion time randomization : 1 . Patients ( male female ) diagnose relapse form MS. 2 . Currently treat b-IFN ( accordance FDA approve dose schedule ) 12 48 month inclusive . 3 . All level disability 4 . Age 18-65 year inclusive 5 . Subjects must willing follow 6-month study period . Exclusion Criteria : Candidates exclude study entry follow exclusion criterion exist time study initiation . 1 . Patients prior b-IFN NAb test ( whether positive negative ) . 2 . Patients currently treat treat within 6 month prior screen combination therapy ( b-IFN plus immunosuppressant/immunomodulatory ) IV steroid ( either pulse relapse ) . 3 . Unwillingness inability comply requirement protocol include presence condition ( physical , mental , social ) likely affect subject 's ability comply study protocol . 4 . Any reason , opinion Investigator , subject determine unsuitable enrollment study . Treatment Groups : This multi-center , open-label study approximately 300 ( 200 NAb+ patient 100 NAb- patient ( 50 BAb+ 50 BAb- ) ) relapse MS patient compare b-IFN induced biomarker response follow b-IFN injection neutralize antibody positive vs. antibody negative patient . Subjects currently three b-IFN preparation ( Avonex ( Interferon b-1a 30 mcg IM Q 7 day ) , Rebif ( Interferon b-1a 22 44mcg SC TIW ) , Betaseron ( Interferon b-1b 250mcg SC QOD ) ) enrol one 3 group : Group 1 : Approximately 200 subject enrol NAb+ ( titer ³ 20NU/ml ) Group 2 : Approximately 50 subject enrol BAb- ( titer &lt; 8U ) NAb- ( titer &lt; 20 NU/ml ) Group 3 : Approximately 50 subject enrol BAb+ ( titer ³8U ) NAb- ( titer &lt; 20 NU/ml )</brief_summary>
	<brief_title>A Serologic Study Correlate Beta-IFN NAb Titers Beta-IFN Induced Biomarker Response Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>1 . Patients ( male female ) diagnose relapse form MS. 2 . Currently treat bIFN ( accordance FDA approve dose schedule ) 12 48 month inclusive . 3 . All level disability 4 . Age 1865 year inclusive 5 . Subjects must willing follow 6month study period . 1 . Patients prior bIFN NAb test ( whether positive negative ) . 2 . Patients currently treat treat within 6 month prior screen combination therapy ( bIFN plus immunosuppressant/immunomodulatory ) IV steroid ( either pulse relapse ) . 3 . Unwillingness inability comply requirement protocol include presence condition ( physical , mental , social ) likely affect subject 's ability comply study protocol . 4 . Any reason , opinion Investigator , subject determine unsuitable enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>MS</keyword>
</DOC>